$0.00
0.00%
Nasdaq, Oct 01, 04:00 pm EDT.
ISIN
US87184Q1076
Symbol
SYRS

Syros Pharmaceuticals, Inc. Stock price

$0.00
+0.00 0.00% 1M
+0.00 100.00% 6M
+0.00 0.00% YTD
+0.00 300.00% 1Y
-3.21 99.99% 3Y
-43.70 100.00% 5Y
-139.70 100.00% 10Y
-181.50 100.00% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.00 0.00%
ISIN
US87184Q1076
Symbol
SYRS
Industry

Is Syros Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$10.0k
Enterprise Value
$-17.2m
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
negative
P/S | estimate
0.0 | -
EV/Sales | estimate
negative | -
EV/FCF | ex SBC
0.2 | 0.2
P/B
0.0
Financial Health
Equity Ratio
9.9%
Return on Equity
-987.7%
ROCE
-
ROIC
-
Debt/Equity
-
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | -100.0%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
-
Short interest
3.8%
Employees
68
Rev per Employee
$150.0k

Syros Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Syros Pharmaceuticals, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Syros Pharmaceuticals, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Syros Pharmaceuticals, Inc.

Sep '24
+/-
%
0.39 0.39
96% 96%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
22% 22%
5,967%
- Research and Development Expense 89 89
23% 23%
22,728%
-110 -110
17% 17%
-28,251%
- Depreciation and Amortization 1.34 1.34
50% 50%
344%
EBIT (Operating Income) EBIT -112 -112
18% 18%
-28,596%
Net Profit -98 -98
7% 7%
-25,082%

In millions USD.

Don't miss a Thing! We will send you all news about Syros Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425 and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Head office United States
CEO Gerald Quirk
Employees 68
Founded 2011
Website syros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today